Literature DB >> 21504732

Increasing hydrophobicity of residues in an anti-HIV-1 Env peptide synergistically improves potency.

Michael Y K Leung1, Fredric S Cohen.   

Abstract

T-20/Fuzeon/Enfuvirtide (ENF), a peptide inhibitor of HIV-1 infection, targets the grooves created by heptad repeat 2 (HR2) of Env's coiled-coil, but mutants resistant to ENF emerge. In this study, ENF-resistant mutants--V38A, N43D, N43D/S138A, Q40H/L45M--were combined with modified inhibitory peptides to identify what we believe to be novel ways to improve peptide efficacy. V38A did not substantially reduce infectivity, but was relatively resistant to inhibitory peptides. N43D was more resistant to inhibitory peptides than wild-type, but infectivity was reduced. The additional mutation S138A (N43D/S138A) increased infectivity and further reduced peptide inhibitory potency. It is concluded that S138A increased binding of HR2/ENF into grooves and that S138A compensated for electrostatic repulsion between N43D and HR2. The six-helix bundle structure indicated that E148A should increase hydrophobic interactions between the coiled-coil and peptide. Importantly, the modifications S138A and E148A in the same peptide retained potency against ENF-escape mutants. The double mutant's increase in potency was greater than the increases from the sum of S138A and E148A individually, showing that these two altered residues synergistically contributed to peptide binding. Isothermal titration calorimetry established that hydrophobic substitutions at positions S138 and E148 improved potency of inhibitory peptides against escape mutants by increasing enthalpic release of energy upon peptide binding.
Copyright © 2011 Biophysical Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21504732      PMCID: PMC3077694          DOI: 10.1016/j.bpj.2011.02.053

Source DB:  PubMed          Journal:  Biophys J        ISSN: 0006-3495            Impact factor:   4.033


  43 in total

1.  A leucine zipper-like sequence from the cytoplasmic tail of the HIV-1 envelope glycoprotein binds and perturbs lipid bilayers.

Authors:  Y Kliger; Y Shai
Journal:  Biochemistry       Date:  1997-04-29       Impact factor: 3.162

2.  Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.

Authors:  Eva Poveda; Berta Rodés; Jean-Louis Labernardière; José Miguel Benito; Carlos Toro; Juan González-Lahoz; Jean-Louis Faudon; François Clavel; Jonathan Schapiro; Vincent Soriano
Journal:  J Med Virol       Date:  2004-09       Impact factor: 2.327

Review 3.  Resistance to enfuvirtide, the first HIV fusion inhibitor.

Authors:  Michael L Greenberg; Nick Cammack
Journal:  J Antimicrob Chemother       Date:  2004-07-01       Impact factor: 5.790

4.  A trimeric structural domain of the HIV-1 transmembrane glycoprotein.

Authors:  M Lu; S C Blacklow; P S Kim
Journal:  Nat Struct Biol       Date:  1995-12

5.  HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.

Authors:  M K Lawless; S Barney; K I Guthrie; T B Bucy; S R Petteway; G Merutka
Journal:  Biochemistry       Date:  1996-10-22       Impact factor: 3.162

6.  Atomic structure of the ectodomain from HIV-1 gp41.

Authors:  W Weissenhorn; A Dessen; S C Harrison; J J Skehel; D C Wiley
Journal:  Nature       Date:  1997-05-22       Impact factor: 49.962

7.  Core structure of gp41 from the HIV envelope glycoprotein.

Authors:  D C Chan; D Fass; J M Berger; P S Kim
Journal:  Cell       Date:  1997-04-18       Impact factor: 41.582

8.  Emergence of a drug-dependent human immunodeficiency virus type 1 variant during therapy with the T20 fusion inhibitor.

Authors:  Chris E Baldwin; Rogier W Sanders; Yiqun Deng; Suzanne Jurriaans; Joep M Lange; Min Lu; Ben Berkhout
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

9.  Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism.

Authors:  J K Judice; J Y Tom; W Huang; T Wrin; J Vennari; C J Petropoulos; R S McDowell
Journal:  Proc Natl Acad Sci U S A       Date:  1997-12-09       Impact factor: 11.205

10.  Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.

Authors:  Stefano Menzo; Antonella Castagna; Alessia Monachetti; Hamid Hasson; Anna Danise; Elisabetta Carini; Patrizia Bagnarelli; Adriano Lazzarin; Massimo Clementi
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

View more
  1 in total

1.  Molecular dynamics studies of the inhibitor C34 binding to the wild-type and mutant HIV-1 gp41: inhibitory and drug resistant mechanism.

Authors:  Xueting Ma; Jianjun Tan; Min Su; Chunhua Li; Xiaoyi Zhang; Cunxin Wang
Journal:  PLoS One       Date:  2014-11-13       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.